Cargando…

Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers

WHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of chal...

Descripción completa

Detalles Bibliográficos
Autores principales: Levine, Myron M, Abdullah, Salim, Arabi, Yaseen M, Darko, Delese Mimi, Durbin, Anna P, Estrada, Vicente, Jamrozik, Euzebiusz, Kremsner, Peter G, Lagos, Rosanna, Pitisuttithum, Punnee, Plotkin, Stanley A, Sauerwein, Robert, Shi, Sheng-Li, Sommerfelt, Halvor, Subbarao, Kanta, Treanor, John J, Vrati, Sudhanshu, King, Deborah, Balasingam, Shobana, Weller, Charlie, Aguilar, Anastazia Older, Cassetti, M Cristina, Krause, Philip R, Restrepo, Ana Maria Henao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499532/
https://www.ncbi.nlm.nih.gov/pubmed/32857836
http://dx.doi.org/10.1093/cid/ciaa1290
Descripción
Sumario:WHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2’s potential to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.